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Abstract Alzheimer’s disease and related dementias (ADRDs) are a global crisis facing the aging popula-
tion and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically
across the world, the scientific community can no longer neglect the need for research focusing on
ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer’s Association Interna-
tional Society to Advance Alzheimer’s Research and Treatment (ISTAART; alz.org/ISTAART) com-
prises a number of professional interest areas (PIAs), each focusing on a major scientific area
associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART
scientists and experts to synthesize a cross-PIA white paper that provides both a concise “state-of-
the-science” report of ethnoracial factors across PIA foci and updated recommendations to address
immediate needs to advance ADRD science across ethnoracial populations.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: Alzheimer’s disease; Alzheimer’s related dementias; Diversity; Ethnoracial; Underserved; Translational;
Ethnicity
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1. Introduction
Alzheimer’s disease and related dementias (ADRDs) are
a global crisis facing the aging population and society as a
whole. The number of people aged 65 years and older is
more than 35 million in Japan (the world’s fastest growing
aging population) [1,2], approximately 48 million in the
United States (U.S.) [3], nearly 120 million in China [4],
and 104 million in India (60) [5], and these numbers are
expected to grow rapidly over the next several decades [2–
5]. With this growth, ADRDs are predicted to become the
single greatest challenge facing health care and medical
systems across the world [6]. This includes low- and
middle-income countries [7]. It is anticipated that the nearly
47 million ADRD cases globally will increase by 10 million
new cases each year [8]. Despite the fact that the global pop-
ulation is already ethnically and racially diverse [9–11],
there remain substantial gaps in the scientific literature
regarding the impact of ethnic and racial factors (herein
referred to as ethnoracial) on ADRDs.
The extant literature supports the need for additional
research into the impact of ethnoracial factors on ADRDs.
Ethnoracial factors have been found to be important when
considering biological (e.g., genetic, cerebrospinal fluid
[CSF], and blood proteomics) [12–17] and medical risk
factors for AD (e.g., hypertension, diabetes, obesity,
depression) [14,18]. These factors may be related to
previously demonstrated differences in incidence, timing
of diagnosis, clinical presentation, and course of AD
between different ethnoracial groups [14,19,20].
Ethnoracial factors, with regard to perceptions of the
normality of cognitive changes [21,22], insurance
coverage and access to health care [17,19], and agreement
to participate in clinical trials [17,19,23], are also
previously documented factors for consideration.
Additional factors such as differing emphasis on family
and respect for elders are important considerations when
seeking to enroll diverse ethnoracial groups into research
studies on ADRDs [17,21,24]. Oftentimes, scientists are
not trained to effectively partner with diverse communities
to build trust to facilitate recruiting, communicate
strategies about health research to study potential
participants, and develop culturally informed retention
strategies. For example, there are oftentimes few, if any,
researchers or staff from underrepresented groups on the
research teams [25]. Study design resources and expertise
barriers include insufficient budgets for recruitment costs,
limited resources to translate documents or adapt literacy
levels, inability to develop relationships with minority phy-
sicians [26], and limited expertise to culturally tailor and
translate study documents. Participant-level barriers, more
often cited than those regarding scientists and study design,
reflect a myriad of concerns such as mistrust, and limited
knowledge about clinical research that affect both recruit-
ment and retention [27]. These factors are relevant to each
topic area covered below. In the U.S., the 2012 National
Alzheimer’s Project Act specifically calls for increased
enrollment of diverse ethnoracial populations into ADRD
research studies.
The Alzheimer’s Association International Society to
Advance Alzheimer’s Research and Treatment (ISTAART;
alz.org/ISTAART) comprises a number of Professional In-
terest Areas (PIAs), each focusing on a major scientific
topic associated with ADRDs. These PIAs include leading
scientists from across the globe with substantial expertise
covering crucial topics for ADRDs. Previous reviews have
documented factors contributing to or associated with eth-
noracial disparities in ADRD research [17,28,29]. To
expand on prior work on the topic, we leveraged the
expertise of an international group of ISTAART
scientists to synthesize a cross-PIA white paper to accom-
plish the following goals:
1. Provide a concise “state-of-the-science” report of eth-
noracial factors across PIA foci.
2. Provide recommendations regarding most immediate
needs to advance ADRD science across ethnoracial
populations.
3. Provide a working model that provides specific key
foci for advancing the field of health disparities in
ADRDs.
This white paper is organized into the following sections
with specific contributions from each ISTAART PIA.
 Factors related to disease detection and biomarkers
B Reserve, resilience, and protective factors PIA
B Diversity and disparities PIA
B Neuroimaging PIA
B Electrophysiology PIA
B Biofluid-based biomarkers PIA
B Immunity and neurodegeneration PIA
 Factors related to interventions and methods
B Clinical trials advancement and methods PIA
B Nonpharmacological interventions PIA
 Ethnoracial factors related to subjective concerns and
affect in ADRDs
B Subjective cognitive decline PIA
B Neuropsychiatric syndromes PIA
 Ethnoracial factors related to atypical AD and other
ADRDs
B Atypical Alzheimer’s disease and associated syn-
dromes PIA
B Down syndrome and Alzheimer’s disease PIA
B Vascular cognitive disorders PIA
 Other factors related to cognitive impairment and de-
mentia
B Perioperative cognition and delirium PIA
B Nutrition, metabolism, and dementia PIA
B Technology PIA
 List of recommendations to collectively and collabora-
tively advance the gaps identified by the respective
PIAs
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B All PIAs, including specific methodological consid-
erations from the design and data analytics PIA
 Advancing the Science of Health disparities in ADRDs
B All PIAs
1.1. Factors related to disease detection and biomarkers
in ADRDs
1.1.1. The influence of ethnoracial factors on reserve,
resilience, and protective factors
Cognitive reserve is a heuristic to help explain individual
differences in brain health and cognition relative to aging
and brain disease [30–32]. These individual differences
could reflect higher capital (higher to start with), better
maintenance (lower decline), or greater resilience/
tolerance and compensation capacities [30–32].
Very little research has assessed whether cognitive
reserve differs across ethnoracial groups. Because ethnora-
cial groups are characterized by distinct social and behav-
ioral practices and may have different genetic background,
differences in reserve can be expected as a function of ethno-
racial factors. Differences in cognitive reserve might in turn
explain differences in the prevalence or incidence of AD or
in the age at disease onset between ethnoracial groups
[5,6,29,33]. For instance, some ethnoracial populations are
characterized by a lack of formal education, which is
strongly associated with lower cognitive reserve [34]. How-
ever, years of education has been shown to be a poor reflec-
tion of the value of educational experience and native ability
among ethnoracial groups, whereas literacy levels may be
more strongly associated with reserve in diverse cohorts
[35,36].
Differences in reserve across ethnoracial groups may be
reflected in differences in (1) the baseline capital (of brain
health and cognition), (2) the maintenance of this capital
over time, and (3) the resistance/resilience of cognitive per-
formance to pathological brain changes. Empirical evidence
for the two first cases (higher capital or better maintenance)
may manifest both by differences in brain health markers
and in cognitive performance in diverse ethnoracial popula-
tions. Difference in maintenance may be more accurately as-
sessed longitudinally by measuring the rate of brain or
cognitive changes over time in different groups. For
instance, African Americans have been found to have a
lower level of global cognition at baseline but a slower
rate of cognitive decline over time, compared with non–
African Americans [37]. An important goal that emerges is
to understand the relative contributions of different genetic
and sociobehavioral/lifestyle factors on the observed differ-
ences among ethnoracial groups in markers of brain health
or cognition.
Finally, differences in resilience/resistance to pathology
among ethnoracial groups may reflect different relationships
between brain health and cognitive performance, for
example, higher levels of brain pathology for a given degree
of cognitive impairment. This was found in one previous
study showing lower CSF phosphorylated-tau (p-tau181)
and total tau (t-tau) levels in African Americans compared
with Caucasians, independent of cognition [15].
1.1.2. The influence of ethnoracial factors on diversity and
disparities
Mungas (2006) presented a model illustrating how ethno-
racial factors, aging, and disease may influence cognitive
ability through the interplay of environment, genes, and
brain structure [38]. Based on this model, the influence
that ethnicity exerts on cognitive functioning would be
modulated by the relationships of multiple factors. In this
section, we address these factors from the perspectives
related to the examinees (i.e., individuals with ADRDs and
caregivers), the examiners, and the specific assessments
used.
Cognitive testing is important for detecting, monitoring,
and distinguishing differences among ADRDs. Most cogni-
tive measures are influenced by linguistic, educational, or
cultural factors, which affect the ability to accurately iden-
tify cognitive impairment and decline in diverse individ-
uals. One of the challenges in assessing ethnoracial
groups is limited formal education and/or high illiteracy
rates and/or cultural nuances to learning and ways of
thinking and solving problems. Lower education has
consistently been associated with worse health status on
a number of outcomes, including dementia. Reading mea-
sures created in one language do not necessarily translate
well into other languages due to a variety of factors [39].
Translating tests across cultural boundaries may not cap-
ture the diverse impact that cultures have on cognition
[40,41]; however, it has been reported that appropriate
adjustment for ethnicity can improve validity of test
findings [42,43]. Neuropsychologists need training to
work with minority groups [17,44]; however, the number
of neuropsychologists with competency to work with
ethnoracial groups and/or possess proficiency in non-
English languages is limited [44,45].
Finally, there are factors related to the cultural validity,
cost-effectiveness, representativeness, and availability of
reliable norms of neuropsychological testing itself. It re-
mains unclear whether translated tests measure constructs
retain a similar meaning within and across cultural groups.
As Luria [46] noted, tests developed and validated for use
in one culture frequently result in experimental failures
and are invalid for use with other cultural groups. For
instance, one study showed that relative difficulty of subi-
tems on the widely used Mini–Mental State Examination
could differ due to cultural factors between the U.S. and
Japan, which could affect sensitivity and specificity of iden-
tifying those with cognitive impairment [47]. Although
many groups have attempted to generate appropriate norma-
tive data across ethnic groups [48–50], the numbers of such
norms remain small and the availability of norms for
individuals with little education remains limited [48,50].
Cost-effective screening tools that have little reliance on
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background education would be of tremendous utility to
large-scale longitudinal epidemiological studies of diverse
ethnoracial groups [45], which is preferable to different sites
using different tests or different versions of the same tests.
1.1.3. The influence of ethnoracial factors on neuroimaging
biomarkers
The utilization of neuroimaging biomarkers in ADRDs
has become increasingly important as structural, functional,
and molecular imaging have led to earlier diagnosis [51–53];
disease staging, including prodromal and preclinical stages
[54,55]; and identification of individuals for clinical trial
participation [56]. However, although great strides have
been made in the field of AD neuroimaging, relationships
between biomarkers and ethnoracial factors remain under-
studied. For example, the 2012 demographic report from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
describes the sample as comprising fewer than 5% African
American or Hispanic participants [57]. As with ADNI,
the Australian Imaging, Biomarkers, and Lifestyle (AIBL)
study of aging [58] does not contain broad representation
from ethnoracial populations. However, the recently initi-
ated Study of Latinos Investigation of Neurocognitive Aging
(SOL/INCA) and Health & Aging Brain among Latino El-
ders (HABLE) studies will soon offer unique opportunities
to study imaging markers related to cognitive aging among
U.S. Latino adults and seniors.
Only a few studies have explored the link between ethno-
racial factors and brain structure along the AD continuum,
and their findings have not been consistent. DeCarli et al.
examined ethnoracial differences in brain volume and cere-
brovascular disease (CVD) and found greater total brain vol-
ume in Hispanics compared with non–Hispanic whites
(nHWs) regardless of diagnosis and found no ethnoracial
differences in CVD measures [59]. Similarly, the Chicago
Health and Aging Project did not find significant interactions
between race and CVD [60]. Although the Washington
Heights-Inwood Columbia Aging Project (WHICAP)
demonstrated greater brain volume in Hispanics and African
Americans than nHWs, they also demonstrated significantly
higher CVD in these groups than nHWs [61]. The Athero-
sclerosis Risk in Communities (ARIC) study has similarly
demonstrated that African American race was a predictor
of an increased number of silent infarcts [62]. In addition,
ARIC demonstrated higher rates of atrophy in African
Americans at baseline and a greater worsening of atrophy
over time [62]. Many of the ethnoracial differences in
CVD are linked to differences in clinical risk factors, but it
is worth noting that some of these risk factors, such as smok-
ing, conferred a more than 4-fold greater risk of CVD in Af-
rican Americans compared to nHWs [63]. There are also
inconsistencies in the research literature with some work
failing to identify ethnoracial differences in the relationships
between brain function and cognition [59,64], whereas
others have shown a significant relationship between
cognitive dysfunction and structure [65,66]. WHICAP
demonstrated that magnetic resonance imaging predictors
of cognition differed across ethnoracial groups. For
example, CVD was associated with worse language and
executive performance in African Americans than nHWs
[65].
Over the last decade, positron emission tomography im-
aging has played a seminal role in the field of AD
neuroimaging, allowing for accurate in vivo detection of b-
amyloid pathology in the brain [67], advancing the field
significantly. However, few published studies have systemat-
ically explored ethnoracial differences in amyloid positron
emission tomography, and no studies have been published
to date in ethnoracial diverse populations that assess the
more recently developed tau imaging agents. The ARIC
study demonstrated significantly increased odds of elevated
brain amyloid in African Americans, after adjusting for
other risk factors such as apolipoprotein E (APOE) ε4,
age, and CVD [68]. Interestingly, the effect size was similar
to thewell-established increased risk of amyloid positivity in
APOE ε4 carriers [69]. In addition, when examining a multi-
ethnic group of nondemented older adults (n 5 116), base-
line cognitive scores were not associated with amyloid
burden. However, higher amyloid levels were associated
with faster longitudinal cognitive decline among African
Americans and APOE ε4 carriers [66]. These data highlight
the need for not only neuroimaging studies with more
diverse samples but also a better understanding of the inter-
action between ethnoracial factors, risk factors, genetics,
and neuroimaging biomarkers in these populations.
1.1.4. The influence of ethnoracial factors on EEG/event-
related potentials-based biomarkers
Compared with structural, molecular, and functional neu-
roimaging techniques, measurements of brain electroen-
cephalographic activity (EEG) during sleep, resting state
(rsEEG), and sensory and cognitive-motor events (event-
related potentials [ERPs]) are less invasive, more readily
accessible, and cost-effective. EEG also has the unique tem-
poral resolution (i.e., milliseconds) to explore abnormal
oscillatory or dynamical neurophysiological mechanisms
of brain neural synchronization and functional connectivity
in individuals with neurological disease and animal models
of diseases [70].
EEG biomarkers are promising candidates for an instru-
mental assessment of neurophysiological brain functions
across disease progression and intervention in AD popula-
tions [71]. Previous EEG biomarker research with ethnora-
cial groups is inconclusive. A study carried out in 236
patients with AD reported a higher risk of unprovoked sei-
zures and epileptiform EEG activity in African Americans
than nHWs [72]; however, this ethnoracial effect was not
replicated in a larger number of individuals diagnosed with
AD (N 5 453) [73].
Motivation for future EEG investigations testing possible
ethnoracial differences in AD rests on previous evidence. An
EEG study on sleep spindles in healthy individuals
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(N5 11,630) reported differences between nHWs and Afri-
can Americans in several EEG features characteristic of
sleep architecture, though these differences decrease with
advanced age [74]. Recent reports have unveiled abnormal
sleep and circadian rhythms with cognitive change and AD
[75], suggesting race/ethnic factors may translate to differ-
ences in AD phenotypes. These studies suggest that ethnora-
cial and genetic factors impact EEG activity.
1.1.5. The influence of ethnoracial factors on biofluid-based
biomarkers
The impact of ethnoracial factors on biofluid-based bio-
markers is well documented across numerous disease pro-
cesses [76–88]. Despite the extensive literature on
biofluid-based biomarkers in other areas, the study of the
link between ethnoracial factors and biofluid-based bio-
markers in ADRDs is nearly nonexistent [89,90]. A meta-
analysis of genome-wide allelic association study data
from several cohorts that included over 500 Hispanics AD
cases to cross-validate four of the top previously identified
AD genes found that the APOE ε4 genotype was signifi-
cantly associated with AD status among all ethnic groups.
However, CLU, CR1, and PICALM were only associated
with AD status among nHWs [89]. In addition, APOE ε4
has been found to be less frequent among Mexican Ameri-
cans diagnosed with mild cognitive impairment (MCI) and
AD [14,91]. The ARIC study reported overlapping and
race-specific genetic markers linked to plasma b-amyloid
levels when comparing African Americans and European
Americans [92]. Ting et al. presented data on a novel
PSEN1 mutation associated with early-onset AD in African
American women [93], whereas a different mutation for
early-onset AD among Caribbean Hispanics has been iden-
tified [94]. Regarding nongenetic blood-based biomarkers,
plasma biomarkers of Ab40, Ab42, and tau were recently
examined among an ethnically diverse sample of females
clinically diagnosed with amnestic mild cognitive impair-
ment (aMCI) [95]. Although increased Ab42 levels were
associated with incidence of aMCI amongHispanics, this as-
sociation did not hold for nHWs or African Americans.
Plasma Ab40 levels were significantly higher among Hispan-
ic aMCI cases than Hispanic controls; this difference was not
found among African Americans. However, plasma total tau
levels were significantly decreased among African Amer-
ican aMCI cases but was not found among nHWs or His-
panics [95]. C-reactive protein (CRP) levels have been
found to be significantly elevated among Mexican Ameri-
cans diagnosed with AD and MCI as compared with non-
Hispanics [96]. Furthermore, the overall proteomic profile
indicative of AD has been found to be different between
Mexican Americans and nHWs [16,97].
Despite the extensive literature on diagnostic biomarkers
of AD in CSF, there has been only one study specifically
examining the impact of ethnoracial factors on these diag-
nostic markers. Howell et al. [15] recently recruited 135
older adults (n 5 65 African Americans and n 5 70
nHWs) spanning normal cognition, MCI, and AD, all of
whom underwent lumbar puncture for an assay of CSF-
based AD pathological markers. The ethnoracial groups
were not significantly different with regard to age, gender,
or education. African Americans had lower levels of CSF
p-tau181, t-tau, and Ab40 levels when compared with
nHWs, whereas Ab42 levels did not vary by the ethnoracial
groups [15]. These results suggest that absolute cut-scores
on these markers may be impacted by ethnoracial factors
and highlight the need for additional work examining the
impact of such factors on CSF biomarkers of ADRDs.
1.1.6. The influence of ethnoracial factors on immunity and
neurodegeneration
Although ethnoracial factors have not been explored with
specific reference to the immune system in AD, there is a
significant body of data that have explored immune differ-
ences across ethnoracial groups in other disorders and sug-
gest further investigation. In vascular disease, for instance,
ethnoracial factors impact expression of adhesion mole-
cules, known to attract lymphocytes to the endothelium
contributing to the formation of atherosclerotic plaques.
Elevated soluble levels of many factors including ICAM-1
and VCAM-1 are associated with increased risk of coronary
artery disease and, more generally, atherosclerosis. Surpris-
ingly, lower levels of soluble ICAM-1 and soluble VCAM-1
were found in individuals of African origin than nHW or
South Asian populations [98,99]. Importantly, these results
remained significant when controlled for homocysteine
and socioeconomic status. These findings were replicated
[100] where soluble ICAM-1 and soluble VCAM-1 were
decreased in African Americans as opposed to nHWAmer-
icans. The results are counter-intuitive given the increased
risk of heart disease in the African American population.
CRP has long been used as a determinant of systemic
inflammation and is frequently measured in the study of
many diseases including CVD, AD, and vascular dementia
[101]. CRP has been shown to be significantly elevated in
the non–Hispanic African American population as opposed
to nHWs [102]. In another study, the CRP elevations in Af-
rican Americans were attenuated significantly when control-
ling for sociodemographic and health variables [103].
Inflammatory cytokines have been explored with respect
to ethnoracial differences. Circulating levels of IL-6 have
been shown to be elevated in African Americans compared
with nHWs in a cross-sectional study of 508men andwomen
with 38%African American participants. The IL-6 elevation
remained when controlling for sociodemographic and health
variables. In the same study, IL-10 and TNFa were found to
be unchanged when comparing African Americans and
nHWs [102]. Other studies examining cytokines present
disparate findings, most likely attributable to the extremely
small sample sizes; some as low as n 5 10 per group. A
good example is IL-1b, where a study concluded IL-1b
levels were elevated in African Americans, but there were
83 African Americans and 24 nHWs in this study [104].
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Another study found a nonsignificant increase in IL-1b in
African Americans as opposed to nHWs, which was in a
sample size of only 10 per group [105]. Finally, a study
with 48 nHWs and 47 African Americans found that there
was no difference in IL-1b levels [106]. These disparate
findings speak to the need to have sufficiently powered
and controlled studies to achieve reliable data and strong
conclusions.
A recent study explored the impact of income and educa-
tional attainment in ethnoracial disparities in inflammatory
risk as it relates to cardiovascular disease [103]. The results
showed that higher CRP levels in non–Hispanic African
Americans and Mexican Americans, compared with
nHWs, were explained entirely by educational attainment.
The authors concluded that studies should move beyond
examining income to include other socioeconomic factors,
with education level being a key part of this. There are no
studies examining neuroinflammation in the brain, and
therefore, we understand very little regarding ethnoracial
microglial differences. The systemic inflammatory differ-
ences, and the immune changes related to cardiovascular
disease, highlight the potential for significant differences
that could have implications for disease progression and
treatment in ADRDs.
1.2. Factors related to interventions and methods
1.2.1. Ethnoracial factors related to clinical trials
There is a well-established widespread failure to success-
fully enroll diverse ethnoracial populations into clinical tri-
als for such ADRD trials. One review found that fewer than
1% of volunteers recruited into AD trials (over 11,000 pa-
tients) were of Hispanic ethnicity and 2% were African
Americans [107]. In general, enrollment of diverse ethnora-
cial groups remains less than 5% of the trial subjects [108];
however, in the U.S., NIH-funded trials appear to have
higher representation of diverse populations when compared
with industry-sponsored trials [107]. Despite this, novel ap-
proaches for recruitment are urgently needed [109]. In addi-
tion to lack of representation in clinical trials,
underrepresented individuals diagnosed with AD are less
likely than nHWs to be prescribed regulatory-approved
(e.g., U.S. Food & Drug Administration, European Medi-
cines Agency) therapeutics [110].
Ethnoracial factors are frequently covaried in statistical
analyses rather than outcomes being reported by subgroups
[111,112]. These factors alone make understanding the
impact of ethnoracial factors on therapeutic response
difficult. ADNI and AIBL studies are frequently used for
estimating sample size for clinical trials, but as noted
earlier, they lack ethnoracial diversity and the estimates
might not be valid if trials were conducted among non-
HWs. Lack of diversity could also mask potential
ethnoracial differences in efficacy due to different biological
mechanisms as discussed earlier, in addition to different
rates of attrition/dropout and medication adherence across
groups. One study, which investigated the structural mag-
netic resonance imaging regions of interest associated with
MCI, showed that once the attrition bias is controlled using
propensity score models, fewer regions were found signifi-
cant [113]. This study underlines the potentially large bias
in study results if attrition bias is neglected and suggests
that documenting rate of attrition for ethnoracial groups in
trials is important.
Utilizing technologies to monitor disease progression
(potential trial outcomes) or identify those who develop
cognitive impairment (study enrichment) has generated
great interest in ADRDs. It is not well known whether ethno-
racial differences may explain willingness in volunteering
for trials that involve modern technologies and naturalistic
methodologies for data collection (e.g., in-home and in-
vehicle monitoring, wearable devices, Internet/webcam).
One study found a volunteer bias for the randomized clinical
trial, where Internet, webcam, and personal computers are
being used intensively [114]. Identifying potential volunteer
bias before the study recruitment begins by closely assessing
past studies or distributing questionnaires, which allows for
assessment of the characteristics of potential participants,
could aid diversification of study participants, especially
when specific types of technologies are involved.
Significant barriers to enrollment of diverse groups into
trials must be addressed. For example, recent work has found
that African Americans are less likely to agree to participate
in preclinical or asymptomatic AD trials [23] and have
higher dropout rates in AD trials when compared with
nHWs [115]. Regardless of these barriers, it is important
that the research community continues to improve recruit-
ment of diverse populations into clinical trials of ADRDs.
This will increase the generalizability of study results as
well as investigate potential biological differences across
ethnoracial groups and their effects on drug efficacy, adverse
events, and drop out/adherence. Recent efforts by the Na-
tional Institute on Aging, with support of the Alzheimer’s
Association, are developing a national strategy for clinical
study recruitment and retention, with a direct emphasis on
local and diverse recruitment and retention strategies [116].
1.2.2. The influence of ethnoracial factors on
nonpharmacological interventions
Nonpharmacological intervention research examines the
effect of therapeutic interventions such as cognitive training,
exercise, functional retraining, and psychological supports
(e.g., counseling or meditation), to delay and/or prevent
the onset of ADRD symptoms or remediate their impact
[117,118]. Relative to pharmacological treatments,
nonpharmacological interventions are more likely to target
not only primary symptoms (e.g., cognitive and functional
decline) but also secondary symptoms that may not be
caused directly by disease but that lead to excess disability
(e.g., stigma, anxiety, reduced self-esteem). In this vein,
nonpharmacological interventions also seek to maintain
the individual’s autonomy and the highest quality of life
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possible during dementia-related cognitive and functional
decline. Researchers working with distinct ethnoracial pop-
ulation groups have developed successful nonpharmacolog-
ical interventions for these groups such as the “Six Arts”
framework developed from a Confucian philosophy that em-
phasizes art, music, and math to improve everyday function
[119]. However, less understood is the generalization of non-
pharmacological intervention studies from one subgroup to
others, especially those with different access, experiences,
and beliefs about medical care.
Sociocultural factors may have an impact on differential
outcomes in nonpharmacological intervention research at
different methodological levels. These factors might hinder
the ability of nonpharmacological intervention researchers
to recruit participants and caregivers from diverse ethnora-
cial groups. Sociocultural factors might influence the reten-
tion of participants in activities, in particular when activities
are less suitable for diverse groups, and in consequence
might influence the outcome of the effectiveness of such in-
terventions. In an analysis of the Resources for Enhancing
Alzheimer’s Caregiver Health (REACH II) trials, re-
searchers concluded that the negative effects of ethnoracial
factors on primary outcomes were diminished after control-
ling for demographic variables such as level of education
and relationship of the caregiver to the person with dementia
[120]. Furthermore, evidence suggests that beliefs, expecta-
tions, quality of life, and even intent-to-participate in non-
pharmacological interventions are impacted by ethnoracial
factors in some chronic conditions [118,121,122], thereby
providing support for the need to study the impact of
ethnoracial factors in nonpharmacological interventions in
ADRDs.
1.3. Ethnoracial factors related to subjective concerns
and neuropsychiatric symptoms in ADRDs
1.3.1. Subjective cognitive decline across ethnoracial
groups
One of the primary challenges ahead of prevention and
treatment interventions in ADRDs is the ability to screen
those at higher risk of developing dementia. The concept
of subjective cognitive decline (SCD; sometimes restricted
to memory only and referred to as subjective memory com-
plaints [SMCs]) has been proposed to unify the research
conceptualization of the earliest nonclinical stage, with po-
tential significance for prevention trials in those with higher
risk of AD [123]. In fact, SCD has been associated with AD-
related neuropathological processes in nonclinical cohorts
[124] and has been identified in individuals aged 30 years
and above [125], which provides a 20- to 30-year window
for potential prevention approaches.
SCD prevalence, incidence, and final outcomes in ethno-
racial groups are areas that have received little attention. One
of the very first yet largest studies of older African Ameri-
cans (n 5 1250) showed that 48.3% of these individuals re-
ported memory problems [126]. The authors concluded that
memory complaints in this group could be explained by
health problems, stressful life events, hearing loss, or depres-
sive signs and symptoms [126]. A more recent publication
on a smaller cohort of African Americans (n5 150) reported
that a third of participants complained about their memory
and cognitive abilities, and their reported cognitive diffi-
culties were mostly associated with increased health prob-
lems, depression, and social problems [127]. Interestingly,
a previous publication reported a discrepancy between
objective cognitive abilities and SMCs reported by African
Americans, where they seemed to report lower numbers of
SMCs in the presence of objectively more impaired abilities
[128]. This finding was reported by a more recent study re-
porting “unique patterns of variability” in SMCs of African
Americans and the relationship between SMCs and psycho-
logical wellbeing [129]. However, it seems that in nonde-
pressed African Americans, SMCs are more related to
cerebrovascular risk factors [130].
The prevalence and incidence, as well as the outcomes of
SCD in other ethnoracial groups, have also been less inves-
tigated. For example, in a memory clinic cohort, Hispanic in-
dividuals reported more cognitive complaints than their
nHW peers [131]. In a recent study of cognitively normal,
community-dwelling Mexican Americans (n 5 319), it
was found that those with SCD exhibited poorer cognition
and were more likely to endorse affective dysfunction
[132]. A qualitative study of SCD in six different ethnic
groups including African Americans, American Indians,
Chinese Americans, Latinos, Vietnamese Americans, and
nHWs indicated that most of the participants were con-
cerned about their cognitive functioning as they age [133].
However, this study did not provide detailed information
on the prevalence, incidence, and follow-up outcomes for
the different ethnoracial groups.
1.3.2. Neuropsychiatric symptoms of AD in ethnoracial
groups
Neuropsychiatric symptoms (NPSs), which include
symptoms such as depression, agitation, and psychosis, are
common in dementia and are associated with faster disease
progression, diminished quality of life, and early institution-
alization [134]. Racial and ethnic disparities in prevalence
and knowledge of NPSs exist in the U.S.; however, few
studies of these disparities of NPSs in AD exist, and they pri-
marily focus on NPS prevalence [135,136]. Because NPSs
create much distress for caregivers and care recipients, it is
critical to determine their impact on different ethnoracial
groups.
The Neuropsychiatric Inventory Questionnaire (NPI-Q)
is the most common measure of NPSs used in AD studies
[137–140]. Existing literature suggests incidence
disparities of NPSs in AD among different ethnoracial
groups. African Americans may experience hallucinations
more frequently [135,136], and noninstitutionalized
African Americans and Latino Americans with dementia
have more frequent behavioral symptoms than nHWs
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[137]. Another study found that being from a member of
some ethnoracial minority groups was associated with psy-
chosis as well [138]. A higher presence and severity of
NPS have been found among Latinos diagnosed with MCI
and AD [14,20,139], which suggests that they may seek
treatment at more advanced stages of AD [137,140].
However, nHWs have been found to exhibit higher levels
of apathy [135,138]. Asian Americans diagnosed with AD
showed frequent emotional disinhibition in one study
[135], but more literature on NPSs in that demographic is
needed. No studies on the prevalence of NPSs in American
Indians with AD currently exist.
Regarding knowledge of AD-related NPSs, Korean
Americans knew less about AD behavioral changes than
about cognitive changes, and Latino caregivers (not specified
by ethnicity) could not attribute NPSs to AD specifically
[141,142]. No literature exists on African Americans’
knowledge of NPSs in AD, but this group appears to view
NPSs as a source of stress in caregiving [143]. African Amer-
icans may cope with NPSs through their faith and assistance
from loved ones and may find behavioral interventions
centered on emotional distress to be less useful [144,145].
No studies were found on access to AD care for NPS
specifically, but minority elders have lower access to
mental health care relative to nHWs and are
institutionalized for AD less frequently [146,147].
Nevertheless, a cultural emphasis on family, respect for
elders, and perceptions of AD symptoms as “natural” parts
of aging may cause members of those minority groups to
take more time before seeking external care for NPSs
[21,24]. African Americans are less frequently prescribed
medications overall for AD and discontinue AD
medication more frequently [148–150]. The only study to
look specifically at medication use for NPSs in AD
(antipsychotics) among different racial groups found that
the usage was higher among Hispanic Americans, likely
due to the higher prevalence ofNPSs in that population [151].
Bridging gaps in NPS prevalence, knowledge, and care
should involve creating tailored interventions for a group
delivered by interventionists who understand (and ideally
come from) cultural dynamics [145,152,153], as well as
through bettering educational outreach to populations with
a lower understanding of NPSs. In addition, much more
research is needed to understand the ethnoracial,
systematic, and possible genetic influences on NPSs
occurrence, neuropathology, and treatment.
1.4. Ethnoracial factors related to atypical ADRDs
1.4.1. The impact of ethnoracial factors in atypical AD and
associated syndromes
Atypical AD was acknowledged in the revised diagnostic
guidelines for AD in 2011 [53] and has since become an um-
brella term encompassing nonamnestic clinical presenta-
tions, early-onset (young) AD, and neuropathologically
defined subtypes of AD (i.e., hippocampal sparing or limbic
predominant) [154–158]. Clinical and neuropathologic
studies suggest that younger age and absence of an APOE
ε4 allele are associated with greater likelihood of atypical
AD [156,159–161]. Regardless of etiology, approximately
5%–10% of individuals present with nonamnestic mild
cognitive impairment (naMCI) [162–164] and 20%–33%
of individuals present with atypical AD [158,165,166].
Compared with typical AD, clinical diagnosis of atypical
AD is often delayed and very little is known about its
pathogenesis, risk factors, natural history, and response to
treatments [167,168] overall, and more so across
ethnoracial groups.
The estimated prevalence and incidence of naMCI in
non–Hispanic African Americans are approximately
16%–18% [162,169] and 3-4 per 100 person-years
[162,170], respectively, with up to a two-fold increased
risk compared with nHWs even after controlling for sex
and education [162,171]. The two-fold increased risk is
suspected to be driven by higher rates of cardiovascular
risk factors among African Americans [172–174],
suggesting a primary or superimposed vascular etiology.
A large cross-sectional study of community-dwelling Co-
lombian adults showed that naMCI was more common in
young-onset dementias and in individuals with lower edu-
cation [175]. Another study investigating the dysexecutive
variant of AD identified that after controlling for covariates
(vascular risk, APOE ε4, and global cognition), the MCI
dysexecutive subgroup was older, less educated, and
more likely identified as African Americans than the
aMCI subgroup. In contrast, the AD dysexecutive subgroup
was younger than the amnestic AD subgroup and did not
differ in education or ethnicity [176]. These results suggest
there may be an even more nuanced aspect related to clin-
ical progression that may need to be accounted for in eth-
noracial studies.
With respect to associated syndromes that may or may
not be related to AD pathology, the prevalence of dementia
among 2011-2013 Medicare beneficiaries ages 68 years
showed that frontotemporal dementia (FTD) was clinically
diagnosed in 0.6% of African Americans, 0.7% of His-
panics, 0.8% of Asian/Pacific Islanders, 0.6% of American
Indians or Alaska Natives, and 1.1% in other/unknown
nonwhite groups [177]. A study examining a community
sample of Hispanics ages 55 years found that approxi-
mately 9% had clinical diagnosis of FTD and 3% had a diag-
nosis of dementia with parkinsonian features [178]. A study
investigating African Americans clinically diagnosed with
FTD revealed AD pathology along with PSEN1 (M139V)
and MAPT polymorphism in exon 7 (A178T) mutations,
suggesting that M139V may present differently among
different ethnoracial groups [179]. Studies also show that
PSEN2 is closely involved in FTD [180,181] and is also
found in Asian [182–184] and African populations [184–
187]. Low-frequency coding variants for genetic susceptibil-
ity to AD and FTD have also been reported in African Amer-
icans, Asians, and Hispanics [188,189].
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Overall, studying clinicopathologic differences in atyp-
ical AD poses great challenges due to their low disease prev-
alence, as well as to the interrelated biopsychosocial and
cultural factors affecting participation in clinical studies
and health outcomes in ethnoracial groups. A paradigm
incorporating those factors is necessary to better understand
and improve dementia treatments in these historically under-
served, ethnoracial populations [190].
1.4.2. The influence of race and ethnicity in Down syndrome
Individuals with Down syndrome (DS) are at high risk for
developing AD compared with the general population [191].
All individuals with trisomy 21 show AD neuropathology by
the age of 40 years, and over 90% show dementia in the sev-
enth decade [192]. The International Workgroup suggests
DS may be a genetically determined atypical AD [154].
There are numerous barriers to early diagnosis of demen-
tia in DS that reflect an interaction between ethnoracial and
health disparities. For example, symptoms of dementia may
be missed or not identified [193]. Often, there are differing
symptom presentations in people with DS relative to spo-
radic AD, and there are concerns about the appropriateness
of the diagnostic tools [194]. Challenges of dementia diag-
nosis in DS within the context of intellectual disability
require specialized expertise and tools [195].
In a preliminary analysis, the incidence of MCI and of
AD was 6% higher among African Americans with DS
than among nHW adults with DS (data from the Aging and
Dementia in Adults with Down Syndrome Study, W. Silver-
man). Age at onset of MCI did not differ between African
American and nHW adults with DS, whereas age at onset
of AD was slightly earlier among African Americans, sug-
gesting a more rapid decline in cognitive function after onset
of MCI. In the general population, the higher rates of AD
among African Americans than among nHWs have been
related to an increased prevalence of cardiovascular risk fac-
tors and CVD, which in turn may elevate risk for AD. These
factors are less likely to influence risk among adults with DS
[191]. Current cohorts under study have relatively few mi-
nority participants, and few studies have examined ethnora-
cial disparities in risk factors for dementia.
Mortality rates also vary across ethnic groups in DS;
disproportionately more African Americans with DS die as
young adults [196]. The ability to determine contributors
to the age of onset of dementia in individuals with DS is
confounded by differences in age at death across different
ethnoracial groups. Disparities are also present in the care
of individuals with DS and dementia. In the U.S., access to
group homes (related to intellectual disability) rather than
dementia special care units is common as group homes are
reported to provide care in a home-like environment, with
more economical costs [197,198]. However, gaps in
services and unmet service needs are reported for adults
with DS in rural/remote settings and their caregivers rely
on informal support [199–201]. In the United Kingdom,
aging-in-place models are encouraged if appropriate support
is available. Most adults with intellectual disability in the
U.S. live at home, and this is more common among diverse
ethnoracial groups (e.g., African Americans, Hispanics)
with DS [202–204]. These differences in care models
impact the caregivers, with poorer health reported for
caregivers of individuals with DS who are also minorities
[203,205,206], which in turn could be a reflection of
socioeconomic status and possibly cultural practices.
Collaborative studies with combined and harmonized
cohorts of older adults with DS are needed to determine
differences in risk factor profiles and to provide accurate
estimates of any differences in risk for AD and rates of
progression after onset.
1.4.3. Ethnoracial factors and vascular cognitive disorders
Vascular cognitive disorders are caused and exacerbated
by health disparities experienced by ethnoracial groups.
Globally, these disparities can be attributed partially to bur-
geoning obesity, combinations of lifestyle factors associated
with poor vascular health, and unknown genetic and lifestyle
susceptibilities among increasing immigrant populations.
Being overweight and obese are cornerstones of vascular
risk, leading to hypertension, type 2 diabetes, CVD, cardio-
vascular disease, and stroke, as well as cognitive impairment
and multiple etiologies dementias.
The prevalence of overweight and obesity is over 50%
among adults in the U.S. and Europe, and within certain
global urban centers such as the Brooklyn Borough of
New York City, the prevalence is over 70%. Of the top 10
causes of death worldwide in 2015 [207], half are related
to obesity, and account for approximately 1/3 of all deaths.
These include ischemic heart disease, CVD/stroke, type 2
diabetes, and ADRDs [207]. Vascular risk is a costly burden.
In Brooklyn, hospitalizations and deaths from heart disease,
diabetes, and disabilities are higher than the New York City
average. Part of the reason is that ethnoracial minority adults
typically present late, at more advanced stages of disease,
and in nontraditional settings, such as the emergency depart-
ment. Given adults from diverse ethnoracial groups also
present with high vascular risk, they are even more
compromised.
Stress is a major facilitator of vascular risk in ethnoracial
minority groups. Stress is a cause, correlate, and conse-
quence of obesity. Not only do stress and obesity lead to
downstream adverse vascular events, they are often accom-
panied by discrimination and unfair treatment, leading to
additional stress responses [208]. Health disparities–
related stress is also associated with ethnoracial differences,
older age, family, employers, stigma due to ethnorace, sex-
ual orientation, infectious disease status, employment status
and/or sex/gender, poor access to health care services, built
environment, lack of social support, depression, and anxiety
[209]. Cumulatively, these stressors challenge social interac-
tions and may manifest as inability to work, difficulties with
personal relationships [210], and challenges to social inclu-
sion [211]. Over the life course, the cost of chronic exposure
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to fluctuating or heightened neuroendocrine responses re-
sulting from repeated or chronic environmental challenges
and social burden that an individual react to as being partic-
ularly stressful [211,212] directly affects neural mechanisms
contributing to cognitive function [213,214].
Potentially modifiable vascular risk factors contribute to
cognitive aging and risk and progression of ADRDs through
their effects on cerebral vasculature. The accumulation of
small vessel cerebral vascular disease that results from years
of exposure to vascular risk is best visualized on T2-
weighted magnetic resonance imaging as white matter hy-
perintensities. Increased white matter hyperintensity burden
is associated with risk for development of ADRDs [215–
217] and progression of symptoms in ADRDs [218] and is
even evident in individuals with autosomal dominant AD
up to 20 years before expected symptom onset [219]. The
severity of white matter hyperintensities differs across racial
and ethnic groups [61] and relates differentially to specific
cognitive outcomes as a function of race/ethnicity
[220,221]. Given the well-documented disparities in
vascular risk factors, differences in CVD, and differential re-
lationships with cognition between racial and ethnic groups,
vascular disease is a major topic of focus with respect to
racial and ethnic disparities in ADRDs.
1.5. Other factors related to cognitive impairment and
dementia
1.5.1. Ethnoracial factors related to perioperative
cognition and delirium
Delirium is a focus for both research investigation and
clinical care around the world. For example, one of the
delirium screening tools, the Confusion Assessment Method
(CAM), has been translated into 19 languages and used in
over 4000 original publications, demonstrating an active
clinical and research interest in delirium [222]. Perioperative
cognitive disorders may contribute to further cognitive
decline and are known to be associated with poor outcomes.
Despite this, there are few studies examining ethnoracial
factors in either delirium or perioperative cognitive disor-
ders, with studies being predominantly restricted to those
who are fluent in English.
Campbell et al. [223] evaluated 1275 older adults aged
65 years who were admitted to general medical hospital
services. The goal of the study was to determine if race is
a factor in the agreement between clinical documentation
and screening results for delirium and cognitive impairment.
The authors compared clinical documentation with scores on
a screening measure (the Short Portable Mental Status Ques-
tionnaire) and found that there were no differences in
delirium documentation rates between African Americans
and non–African Americans. However, African Americans
had a higher adjusted odds ratio than non–African Ameri-
cans for clinical documentation of cognitive impairment
among those who screened positive for impairment on the
Short Portable Mental Status Questionnaire, as well as
among those who screened negative on the Short Portable
Mental Status Questionnaire.
One study examining the recorded diagnosis of delirium
in acute inpatient units found that African Americans were
more likely to receive a confusional diagnosis or an organic
psychoses diagnosis as opposed to a diagnosis of delirium
[224]. Individuals who received the diagnosis of organic
psychoses had longer lengths of stay and higher rate of
discharge to nursing homes. One of the potential explana-
tions for these differences was that elderly African American
individuals are significantly more likely to receive diagnosis
of psychotic disorders than nHWs [225]. Another study
examining the prevalence of delirium among older adults
presenting with psychiatric complaints to an emergency
department, it was found that although minority individuals
(African American and Hispanic) comprised 55.8% of the
study cohort, 74.1% of delirium visits were comprised of mi-
nority individuals [226].
The most frequent etiology of delirium in sub-Saharan
Africa (SSA) reported in the literature is infection including
HIV, typhoid fever, and malaria. However, the number of
older adults is expected to increase by 64% in Africa in
the next 15 years [227], and it is unknown whether the avail-
able expertise of diagnosing and treating delirium by health
care providers in Sub-Saharan Africa can meet the
increasing demand. In addition, with increasing access to
higher levels of care in Sub-Saharan Africa, clinical entities
such as ICU delirium, which is a new concept to many phy-
sicians in these regions, are also emerging.
Cognitive decline associated with anesthesia and surgery
is known to occur in more than 10% of individuals 3 months
postoperatively [228] and has been termed postoperative
cognitive dysfunction (POCD). POCD has been limited to
predominantly English speakers due to limitations of exist-
ing neuropsychological tests, with some limited European
languages included as part of the International Study of
POCD [229]. POCD studies have been undertaken in some
Asian populations, but most of these are limited to very short
follow-up of days rather than weeks, months, or years [230].
It is unclear if POCD precipitates long-term cognitive
decline, but it is known that POCD is associated with poor
outcomes including increased risk of mortality as far as
7.5 years after surgery [231]. Thus, it is important for future
research to focus on ethnoracial factors that may contribute
to perioperative cognitive disorders. The recent recommen-
dations for new nomenclature should assist in facilitating
this research agenda.
1.5.2. Ethnoracial factors related to diet and nutrition
Diet is complex and varies considerably by ethnicity and
socioeconomic status [232–234]. It is well established that
some ethnoracial groups experience diet-related disparities
and consequently have poorer nutrient profiles relative to
nHWs [235,236]. According to the U.S. Behavioral Risk
Factor Surveillance Survey (BRFSS) [237], only 21.3% of
African Americans consume fruits and vegetables 5 times
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per day, the lowest of any U.S. ethnoracial group. Similarly,
in the third National Health and Nutrition Examination Sur-
vey, NHANES (1999–2002), non–Hispanic African Ameri-
cans were 43% less likely than nHWs to meet fruit and
vegetable guidelines [238]. These racial disparities differ
by geographic region. For example, Hispanic groups
consumed lower-quality diets than nHWs, including more
refined carbohydrates and fewer vegetables and fruits
[232,233,239], whereas in other studies, Hispanics had
higher-quality diets than either nHWs or African Americans
[234].
Poor diets and malnutrition are important contributors to
cognitive impairment [240–242]. Nutritional deficiencies in
older people, particularly in minority groups, are common,
but studies across diverse ethnoracial populations are
limited [242–245]. Randomized trials of nutritional
supplements are needed to examine their impact on
ethnoracial groups (e.g., African Americans) that have
known nutritional deficiencies. Unfortunately, most
randomized clinical trials of dietary supplements have not
targeted populations with low nutrient status, and trial
results have been null overall [246]. Conducting dietary sup-
plement trials in diverse ethnoracial populations with
nutrient insufficiencies has the potential to close some of
the ethnoracial disparities in ADRDs.
The few studies that have examined dietary associa-
tions with AD and other brain neurodegenerative out-
comes in multiethnic participants in most cases do not
present their findings by race or ethnic group [241,247–
257]. Rather, these studies have reported P values
(usually null) for tests of effect modification by race/
ethnicity [247,248,250,251,253,257,258]. This is
inadequate as there are clear examples of nutrition
having different cognitive effects by ethnoracial groups
as shown in the Healthy Aging in Neighborhoods of
Diversity Across the Lifespan Study (vitamin E with
various cognitive domains) and the Health, Aging, and
Body Composition study (the Mediterranean diet with
cognitive decline) [259,260].
Cultural differences in dietary practices pose methodo-
logical challenges in dietary assessment. Many food fre-
quency questionnaires have not been designed and tested
to accurately capture the foods, serving sizes, and meal prep-
arations of different cultural groups [261]. Consequently, the
dietary assessments from these studies likely produce biased
estimates of nutrient relations with dementia, particularly for
ethnoracial minority populations. To adequately address eth-
noracial disparities in diet, nutrition, and ADRDs, it is
imperative that greater attention is devoted to cultural vali-
dation of the dietary assessment methods.
1.5.3. Ethnoracial factors related to the development of
technologies
Technology for dementia has developed in several main
areas: assessment of cognitive functions [262] and daily ac-
tivities [263]; direct cognitive [264] or behavioral support
[265]; monitoring [266]; and direct caregiving [267] and
supporting caregivers [268]. Different ethnoracial groups
have been involved in the creation and testing of technolo-
gies, but the potential impact of these differences has not
been explored. The focus of most research has been on the
effectiveness or impact of the technology, with a lack of
consideration of the role ethnoracial factors may play in uti-
lization or impact potential.
Two key issues in development of technology for demen-
tia relate to cognitive function and accessibility of technol-
ogy. Understanding cognitive function is central to
developing technology for individuals with dementia and
this is where the lack of ethnoracial consideration is most
apparent. Much technology development has focused on
improving cognitive assessment [269] to enhance or
improve dementia diagnosis. However, these studies have
not reported on possible inclusion or on differences in cogni-
tive performance and profiles [270] and rate of decline [271]
in ethnoracial minority groups.
There is also limited information available on access to
technology in ADRDs. The “digital divide” is an issue that
reflects socioeconomic factors, whereby lower-income
groups have less access to technologies. There are no exist-
ing survey data on access and use of technologies by people
with dementia that consider ethnoracial factors. However,
we can gain some insight from two large U.S. surveys that
looked at the use of assistive technologies (ATs) by different
racial groups. Reed et al. [272] conducted the Community
Research for Assistive Technology Survey in California.
They divided ATs into three categories: high-tech (e.g., com-
puters), medium-tech (e.g., scooters), and low-tech (e.g.,
magnifiers). The proportion of white respondents (23%) us-
ing high-tech devices was higher than Asian Americans
(16%), African Americans (13%), and double the number
of Latinos (11%) suggesting unequal access to the same
technology [272]. This lack of access and awareness was
echoed in a 2009 U.S. National Health Survey, which looked
at ATs usage across groups with mobility, visual, auditory,
and emotional disabilities [273]. Their findings suggested
that income status, particularly receiving Medicaid or veter-
an’s benefits, and mental impairment reduced the likelihood
of people using ATs [273]. To address these challenges, they
proposed a list of changes including more cultural compe-
tency training, ensuring the attitudes and values are included
in evaluating AT needs among underrepresented groups and
designing effective outreach and health marketing appropri-
ately tailored to different ethnoracial populations. In relation
to dementia technology specifically, a survey of American
and German family caregivers found low awareness of
what technology is available for themselves or the people
they care for [274]. In addition, lack of access to broadband
Internet and limited availability of specialized technologies
have been identified as key barriers to technology for demen-
tia [275]. However, there are signs that the growing need to
address these problems is starting to take hold through recent
efforts to meet the needs of ethnic minority dementia
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caregivers through apps [276], online education [277], You-
Tube [278], and a survey of their preferences for technology
[279].
Overall, there remains a significant dearth in research
specifically designed to understand and address heath dis-
parities in ADRDs. Diverse ethnoracial populations remain
underrepresented in studies across all areas covered by the
PIAs. However, given the substantial amount of work that
has been accomplished across these respective areas, there
remain tremendous opportunities to rapidly advance the
state of the science. Broad areas of immediate need, based
on the information provided above, are provided below.
1.6. Recommendations for advancing the field of health
disparities in ADRDs
As highlighted across each of the major topic areas and
expert groups listed, there remain substantial knowledge
gaps regarding the ADRDs among diverse ethnoracial
groups globally. The science of ADRDs has advanced
considerably over the last few decades, and the same can
be accomplished regarding an understanding of ADRDs
among diverse populations. First and foremost, the expertise
of the various PIAs and global experts across fields needs to
be leveraged to design and implement research programs to
address the gaps identified in a rapid fashion.
Primary recommendations proposed by the working
group are as follows:
 Develop specific health disparities models/frameworks
and implement data-driven strategies for targeted
recruitment and retention of diverse ethnoracial popu-
lations into ADRD observational studies and clinical
trials.
 Identify differing perspectives and views held by eth-
noracial groups regarding ADRD research and inter-
ventions, to tailor appropriate methodologies for
addressing gaps identified here as well as widely
disseminating findings.
 Uniformly, examine the prevalence of specific life ex-
periences/status (e.g., poverty, war/conflict, stigma,
disability, sex, gender) and whether they play a role
in ADRD disparities among diverse ethnoracial groups
across countries.
 Create training modules, webinars, and related educa-
tional opportunities for researchers, payors, funders,
community members, and even research participants
to learn how to effectively develop diverse and inclu-
sive study designs and recruitment and retention strate-
gies in ADRD studies.
 Train practitioners and researchers (e.g., neuropsy-
chologists, neurologists, geriatricians), including those
from diverse ethnoracial groups, to implement cultur-
ally appropriate research methodologies (e.g., assess-
ments, interviews, interventions) across different
ethnoracial groups.
 Develop and validate appropriate research tools along
with appropriate use and interpretative guidelines
(e.g., normative references). This can include genera-
tion of instruments that can be used across groups,
development of novel tools that are group-specific,
and the development of appropriate analytic methods
for working across tools when needed.
 Establish collaborative infrastructure across existing
longitudinal registries and cohorts that include diverse
ethnoracial populations to address gaps identified here.
Also, leverage existing infrastructures and knowledge-
base for the establishment of additional targeted
research cohorts to advance the field of health dispar-
ities in ADRDs.
 Implement methodological strategies that enable post
hoc analyses across diverse groups, comparisons
across longitudinal cohorts; consistently report ethno-
racial subgroup data even when not analyzed; and
include refreshment samples in cohort studies to main-
tain statistical power—including addition of replace-
ment for attrition in ongoing studies that are not
representative of ethnoracial groups with diverse pop-
ulations.
 Implement analytic methods to weigh observations
from underrepresented groups to attenuate the impact
of small sample size; investigate the impact of ethnora-
cial disparities on retention, attrition, and mortality;
and consistently report ethnoracial subgroup data,
even if such differences are not analyzed due to low
group sample sizes.
 Develop and validate statistical models of risk and pro-
tective factors germane to ethnoracial groups,
including complex interaction terms to better refine
prevalence and incidence of ADRDs between different
groups.
 Employ structured “precision medicine” and “preci-
sion public health” approaches to combine, translate,
and share findings from ADRDs research including
ethnoracial groups across the world to target and
continually refine diagnostics, disease monitoring,
treatment, and development of new therapeutics.
 Include diverse ethnoracial groups in studies exam-
ining sociocultural, biomarker, biological mechanism,
and all other aspects of ADRD science.
 Develop and disseminate educational materials
regarding ADRDs specifically focused on caregivers
from diverse groups; include caregivers from diverse
ethnoracial groups in scientific inquiries addressing
caregiver and family needs.
1.7. Advancing the Science of Health disparities
in ADRDs
As previously discussed, there are several gaps in the
extant literature in many of the key areas of science currently
being examined in ADRDs. Aside from the large gap in
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literature examining ethnoracial factors in ADRDs docu-
mented by this working group, there is also no comprehen-
sive framework to address the gaps. Specifically, the vast
majority of the science conducted in the articles reviewed
addressed one question at a time without the end in mind
(i.e., a comprehensive understanding of the full complexity
of ADRDs, including ethnoracial factors). To advance the
understanding of ethnoracial factors in ADRDs, the field
needs to not only directly test importance of ethnoracial fac-
tors but also test these constructs within the context of the
“big picture” including, but not limited to, factors such as
gender, neuropathology (e.g., the 2018 NIA-AA research
criteria for AD explicitly for testing of these new concepts
in diverse populations), molecular biology, environmental
factors, and more.
If the comprehensive framework is to explicitly test and
understand the complexity of ADRDs, then more advanced
analytic modeling approached are needed as is longitudinal
data. Studies that iteratively propose a unique hypothesis,
test the hypothesis, refine the question, and start-over using
large-scale longitudinal data are needed. Multiscale
modeling, advanced artificial intelligence learning tools,
and structural equation modeling are some of the tools that
are explicitly designed to manage such large-scale and com-
plex questions. The statistical/bioinformatics models can
grow and expand iteratively as the hypotheses are tested,
refined, and reanalyzed. Many of these tools were refined
in the human genome project but have been applied to life
sciences at large scale. The translational work in ADRDs
has begun to break down silos; however, the questions posed
do not directly test the complexity of the problem faced. If
these more complex tools are utilized, the complexity of eth-
noracial factors, within the context of ADRDs more broadly
will become more in focus. This approach can lead to a pre-
cision medicine approach to treating and preventing AD.
To continue the momentum of this working group and
other ongoing efforts, we propose that a formal meeting
occur in conjunction with the National Alzheimer’s Project
Act meeting (or other meeting), specifically to address the
advancement of health disparities in ADRDs. This meeting
would serve as a “think tank” on how to move the field for-
ward rather than a venue for individuals to present their
recent (or remote) findings. Experts from diverse back-
grounds (epidemiology, health disparities, neuropathology,
sociology, etc.) would be invited to discuss and provide stra-
tegies for next steps to advance the field.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional sources (e.g., PubMed) and
meeting abstracts and presentations. Several recent
publications have described the role of ethnoracial
factors on the incidence, diagnosis, and clinical pre-
sentation of Alzheimer’s disease and related demen-
tias (ADRD). These relevant citations are
appropriately cited.
2. Interpretation: The manuscript clearly identifies the
study of ethnoracial factors in key topic areas of
ADRD science as substantially lacking. Despite the
global search for improved diagnostic and therapeu-
tic understandings of ADRD, research is needed on
these topics across ethnoracial populations.
3. Future directions: Experts from Professional Interest
Areas of ISTAART provide specific immediate needs
on ethnoracial research across a wide range of topic
areas that, when dealt with, will greatly advance
the field of ADRD. Addressing these needs will be
key to implementing culturally-appropriate interven-
tions, as well as improving access to care for ethno-
racial groups.
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